SPRAVATO® is covered by most major insurance plans, but coverage does not activate without a prior authorization process, and that process involves documentation requirements that patients are not always told about in advance. For patients in Oregon considering SPRAVATO® for difficult-to-treat depression, the difference between getting to treatment and staying stuck at the insurance step is usually a matter of knowing what to prepare. This post covers what insurers typically require, what support exists when coverage falls short, and how we handle the verification process at Catalyst Psychiatry in Corvallis.
SPRAVATO® and Insurance: Understanding Your Coverage
The U.S. Food and Drug Administration approved SPRAVATO® specifically for adults with treatment-resistant depression and, separately, for adults with major depressive disorder with active suicidal ideation (U.S. Food and Drug Administration). That approval status is what most major insurance plans use as the basis for coverage decisions. Because SPRAVATO® is an FDA-approved medication for defined psychiatric indications, it is not in the same coverage category as experimental or off-label treatments, and most large commercial insurers have a coverage pathway for it.
Catalyst Psychiatry is in-network with the following plans: Providence, Pacific Source, First Choice Health, TriCare, Moda, Compsych, Samaritan Choice, Optum, UHC Commercial, United Behavioral Health, Triwest, and Regence Blue Cross Blue Shield. At this time, we are not accepting Medicare, Medicare Advantage plans, or Oregon Health Plan for SPRAVATO® treatment. Patients whose coverage is through a plan not on this list should call their insurer directly and ask about SPRAVATO® (esketamine nasal spray) as a specific line item on their benefits.
Results vary by individual, and what insurance covers varies by plan. Verifying your specific coverage before any treatment begins is essential, and it is something we do as part of your consultation appointment rather than leaving it to you.
Navigating Prior Authorization for SPRAVATO® in Oregon
What Prior Authorization Means in Practice
Prior authorization (commonly abbreviated PA) is a standard process by which an insurance company reviews clinical documentation before approving coverage for a specific treatment. It is required for SPRAVATO® by most insurers, and a prior authorization requirement is not the same as a denial. It is a step that needs to be completed correctly.
Our clinical team handles the prior authorization submission on your behalf. You do not have to manage the paperwork or call your insurer to initiate it. What we need from you is accurate and complete information about your psychiatric and medication history, which we gather during your initial consultation. If you are coming to us having received prior psychiatric care elsewhere, bringing records of your previous medication trials, including what was prescribed, at what dose, and for how long, is the most useful thing you can do to help the process move efficiently. We can request records, but having them available from the start reduces delays.
What Insurers Typically Require
Insurance companies set their own prior authorization criteria for SPRAVATO®, and these vary by plan. In general terms, most insurers require documentation that a patient meets the clinical criteria for treatment-resistant depression, meaning they have not responded adequately to two or more antidepressant medications at therapeutic doses for sufficient durations. The exact number of prior trials required, which medication classes must be represented, and what level of clinical documentation is needed differs across plans.
Some insurers also require documentation from a board-certified psychiatrist, which is satisfied by a formal evaluation at Catalyst Psychiatry. Our providers conduct all evaluations in accordance with DSM-5 criteria (the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition), and our documentation reflects the detail that prior authorization submissions require.
Our team is familiar with the prior authorization requirements of the plans we work with. We approach each submission knowing what a given insurer is likely to ask for and preparing the documentation accordingly. That familiarity makes the process more efficient and reduces back-and-forth with insurers.
When a Prior Authorization Is Denied
A first denial is not a final answer. Insurance companies deny prior authorizations for a range of reasons, many of which are addressable through the appeals process. Common reasons for initial denials include incomplete documentation of prior medication trials, missing records from previous providers, or a plan’s internal criteria that differ slightly from the clinical standard. Most of these can be addressed.
At Catalyst Psychiatry, we assist with prior authorization appeals when an initial request is not approved. We communicate with you transparently about where the process stands and what the next steps are. A denial does not automatically mean SPRAVATO® is not a covered option for you. Discussing the specifics of the denial with your provider is the right step before concluding that coverage is unavailable.
When Coverage Falls Short and What Happens at Your Consultation
For patients whose coverage has limits, whose plan falls outside our network, or who face out-of-pocket costs that create a real barrier, the SPRAVATO® With Me patient support program is a resource worth knowing about. This program, offered through Johnson & Johnson, includes tools to help patients understand their insurance benefits, navigate prior authorization, and, for those who qualify, access financial assistance that can reduce what they pay out of pocket (Johnson & Johnson).
Our billing team can connect you with this program directly. We consider cost to be a legitimate part of the treatment conversation, not something to sort out after the fact. No treatment at Catalyst Psychiatry is recommended before you have a clear picture of what it will cost you.
The consultation at Catalyst Psychiatry is where everything related to coverage gets clarified. We verify your insurance, assess your eligibility for SPRAVATO®, and initiate the prior authorization process if you are a candidate. If there are coverage questions or gaps, we address them at that stage, before any sessions are scheduled. The goal is that you leave your consultation knowing whether SPRAVATO® is covered under your plan, what your out-of-pocket responsibility looks like, and what the path forward is.
If you want to get a general sense of your SPRAVATO® coverage before your consultation, calling the member services number on the back of your insurance card and asking specifically about SPRAVATO® (esketamine) coverage and prior authorization criteria is a direct way to do it. Those answers give you a starting point. Our team handles the formal verification and submission from there.
Frequently Asked Questions About SPRAVATO® Insurance Coverage
Does insurance cover SPRAVATO® treatment?
SPRAVATO® is covered by most major insurance plans for its FDA-approved indications. Coverage requires prior authorization from your insurer, and specific criteria vary by plan. We verify your coverage during your consultation appointment before any treatment is recommended, so you know what your plan covers before committing to anything. Patients with coverage questions can also call their insurer directly and ask about SPRAVATO® (esketamine nasal spray) prior authorization requirements.
What is a prior authorization and do I have to manage it myself?
Prior authorization is a clinical documentation review that your insurance company requires before approving coverage for a specialty treatment like SPRAVATO®. Our clinical team handles the submission on your behalf. We gather the information we need during your consultation, prepare the documentation, and submit it directly to your insurer. You do not have to initiate or manage the process yourself, though having your prior medication records available from the start helps things move faster.
What if my prior authorization is denied?
A first denial is often reversible through the appeals process. Denials frequently result from incomplete documentation or documentation gaps that can be addressed. At Catalyst Psychiatry, we assist with prior authorization appeals and communicate with you about what the denial said and what the path forward looks like. A denial does not necessarily mean coverage is unavailable. Discuss the specifics with your provider before concluding otherwise.
What if I cannot afford SPRAVATO® even with insurance?
The SPRAVATO® With Me patient support program, offered through Johnson & Johnson, includes financial assistance resources for eligible patients and tools to help with insurance navigation. Our front desk team can connect you with this program directly. We also discuss out-of-pocket costs openly during the consultation so there are no surprises after treatment begins.
Does Catalyst Psychiatry accept Medicare or Oregon Health Plan for SPRAVATO®?
At this time, we are not accepting Medicare, Medicare Advantage plans, or Oregon Health Plan for SPRAVATO® treatment. Patients covered under these plans who are interested in SPRAVATO® should call our office to discuss their situation, as coverage options and program access can evolve.
Key Takeaways
- SPRAVATO® is covered by most major insurance plans for its FDA-approved indications; coverage requires prior authorization, which our clinical team handles on your behalf.
- Catalyst Psychiatry is in-network with Providence, Pacific Source, First Choice Health, TriCare, Moda, Compsych, Samaritan Choice, Optum, UHC Commercial, United Behavioral Health, Triwest, and Regence Blue Cross Blue Shield; we are not currently accepting Medicare, Medicare Advantage, or Oregon Health Plan for SPRAVATO®.
- A first prior authorization denial is not a final answer; most denials are addressable through the appeals process, and our team assists with appeals.
- The SPRAVATO® With Me program through Johnson & Johnson offers financial assistance resources for eligible patients when coverage falls short.
- Insurance verification takes place during your consultation appointment before any treatment is recommended, and results vary by individual.
Understanding your insurance coverage for SPRAVATO® does not have to be something you figure out on your own. At Catalyst Psychiatry in Corvallis, the consultation appointment is where coverage gets verified, prior authorization gets initiated, and cost questions get answered directly. Call us at 541-730-4400 or reach out through our website to schedule. The decision about whether to pursue treatment is yours, and having a clear picture of the coverage landscape is part of making it with confidence.
References
U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression, available only through a restricted program. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
Johnson & Johnson. SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression. https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression
Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. SPRAVATO® treatment should only be pursued under the supervision of a licensed psychiatric provider familiar with your full medical and psychiatric history. Insurance coverage, prior authorization outcomes, and financial assistance eligibility vary by individual plan and circumstance. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline, or go to your nearest emergency room.